Synthesis, Biological Evaluation, and Molecular Modeling of Natural and Unnatural Flavonoidal Alkaloids, Inhibitors of Kinases
- 1 March 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (6) , 2811-2819
Abstract
The screening of the ICSN chemical library on various disease-relevant protein kinases led to the identification of natural flavonoidal alkaloids of unknown configuration as potent inhibitors of the CDK1 and CDK5 kinases. We thus developed an efficient and modular synthetic strategy for their preparation and that of analogues in order to determine the absolute configuration of the active natural flavonoidal alkaloids and to provide further insights on the structure–activity relationships in this series. The structural determinants of the interaction between some flavonoidal alkaloids with specific kinases were also evaluated using molecular modeling.Keywords
This publication has 26 references indexed in Scilit:
- Apoptotic Effects of Chrysin in Human Cancer Cell LinesInternational Journal of Molecular Sciences, 2010
- Function and regulation of Dyrk1A: towards understanding Down syndromeCellular and Molecular Life Sciences, 2009
- Cyclin-dependent kinase inhibitors as potential targeted anticancer agentsInvestigational New Drugs, 2009
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myelomaLeukemia, 2009
- Nitrogen-containing flavonoid analogues as CDK1/cyclin B inhibitors: Synthesis, SAR analysis, and biological activityBioorganic & Medicinal Chemistry, 2008
- Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: Design, synthesis, and biological evaluationBioorganic & Medicinal Chemistry Letters, 2007
- Pharmacological inhibitors of glycogen synthase kinase 3Trends in Pharmacological Sciences, 2004
- The CLK Family Kinases, CLK1 and CLK2, Phosphorylate and Activate the Tyrosine Phosphatase, PTP-1BJournal of Biological Chemistry, 1999
- Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical TrialsInvestigational New Drugs, 1999
- Anti-HIV and Cytotoxic Alkaloids from Buchenavia capitataJournal of Natural Products, 1992